Genmab announced it will present 22 abstracts on epcoritamab, a bispecific antibody for B-cell malignancies, at the 2026 American Society of Hematology (ASH) Annual Meeting. Highlights include first Phase 3 results from the EPCORE DLBCL-4 study evaluating epcoritamab plus lenalidomide in relapsed or refractory diffuse large B-cell lymphoma. The data showcase epcoritamab's versatility as monotherapy and in combination therapies across multiple lymphoma subtypes and treatment lines. Genmab and partner AbbVie aim to expand epcoritamab's use globally, with ongoing trials and regulatory efforts.
AbbVie, Genmab's partner in developing epcoritamab, is trading at USD 291.79 on Pluang with a 1-day gain of 2.02%. The stock shows strong investor interest, with 93% of orders as buys. These figures are as of Nov 04, 2026 20:51 WIB.
Exxon Mobil announced its 44th consecutive annual dividend increase, raising its quarterly payout by 4%, supported by strong free cash flow and a solid balance sheet. Chevron, AbbVie, and ONEOK also increased their dividends, backed by robust earning...
AbbVie’s stock reached a new high following a 33% gain this year and an earnings beat with adjusted EPS of $3.82, beating estimates. The company raised its full-year EPS guidance and quarterly dividend, driven by strong sales of Skyrizi and Rinvoq, w...
AbbVie Inc. reported strong Q3 results with revenue up 10.3% year-over-year to $17.4 billion, beating analyst expectations. Non-GAAP earnings per share more than doubled, rising 105.4%. The company's IL-23 antagonist drug Skyrizi saw sales grow 22.7%...
